Antihistamine recall across the US triggered by heartburn drug contamination risk, FDA says
A generic model of the brand-name allergy treatment Zyrtec is below recall across the US attributable to potential cross-contamination with a heartburn drug, based on the Food and Drug Administration.
Drugmaker Unique Pharmaceutical Laboratories is voluntarily recalling antihistamine medicine, generally used to deal with seasonal allergic reactions, over potential cross-contamination with ranitidine, a heartburn drug. Unique Pharmaceutical Laboratories introduced the recall on July 18.
A pharmacy technician noticed what they described as a purple dot on a few of the antihistamine medicine — cetirizine hydrochloride tablets USP 5 mg — when counting and bottling the drugs, based on the FDA’s recall notice. Other tablets have been discolored, alerting the technician to a attainable concern.
The FDA indicated that buyers who’re hypersensitive to elements contained in ranitidine might expertise adversarial unwanted side effects upon publicity, together with hypotension, shortness of breath, problem swallowing, lack of consciousness and different life-threatening reactions.
There have been no experiences of adversarial occasions associated to the recall, based on the FDA.
What merchandise are affected?
The tablets, distributed by Rising Pharma Holdings Inc. to retailers across the US, are packaged in 100-tablet bottles. Products with the following lot numbers, set to run out in October 2028, are below recall:
- GY825029
- GY825030
- GY825031
- GY825032
Rising Pharmaceutical Holdings has notified its clients about the recall and is arranging for the return of all medicine which can be below recall.
Consumers with questions can contact Rising Pharma Holdings straight at 1-844-874-7464, or by e mail at pv@risingpharma.com or qa@risingpharma.com. Patients are inspired to achieve out to their healthcare supplier in the event that they expertise issues associated to the probably contaminated medicine.
